Novartis invests in early technical development capabilities for next-generation biotherapeutics

Novartis invests in early technical development capabilities for next-generation biotherapeutics
Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will bolster its capacity and capabilities for early technical development of biologics. Spanning both drug substance and drug product development, the multi-year investment will be implemented across existing Novartis locations in Switzerland, Slovenia and Austria,